Pricing Log in Create free account

Kalaris Therapeutics Inc. (KLRS) vs Rein Therapeutics Inc. (RNTX)

Kalaris Therapeutics Inc. and Rein Therapeutics Inc. are both Biotechnology companies. Kalaris Therapeutics Inc. and Rein Therapeutics Inc. are of similar size ($52.8M and $51.6M). Across the 8 metrics below, Kalaris Therapeutics Inc. leads on 6 and Rein Therapeutics Inc. on 2.

Valuation

Metric KLRS RNTX Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 1.01 4.01 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.33 n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (85.64%) (281.97%) (32.88%)
Free cash flow yield (70.40%) (45.77%) (23.13%)

Profitability

Metric KLRS RNTX Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (79.91%) (753.55%) (51.96%)
Return on assets (46.02%) (80.62%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KLRS RNTX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 94.50% 44.16% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KLRS RNTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.98 4.27 4.97
Net debt to EBITDA 2.54 0.15 1.01

Dividend

Metric KLRS RNTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KLRS RNTX Biotechnology median
Market cap 51.55m 52.79m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack